Stoma Related Complications and Quality of Life Assessments Ethiopia and Sweden
Stoma Related Complications and Quality of Life Assessment: a Cross-sectional Study With Patients From Ethiopia and Sweden
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Objective: To evaluate the quality of life for patients with ostomy in Ethiopia and Sweden using a general and a specific assessment tool.
Design: Comparative descriptive cross-sectional study. Setting: Tikur Anbessa Specialized Hospital (TASH), Addis Abeba and South General Hospital, Stockholm.
Participants/Exposure: Patients with a permanent ostomy visiting the stoma center in Addis Abeba, patients waiting for ostomy reversal at TASH, and patients visiting the stoma clinic at South General Hospital.
Main outcomes and measure: Quality of life and stoma specific quality of life: EQ5D-5L and Stoma QoL.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Addis Abeba, Ethiopia
- Tikur Anbessa Specialized Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- adult patients (≥ 18 years old)
- having an ostomy for more than two months
- willingness and ability to give informed consent
Exclusion Criteria:
- non-intestinal stoma
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Ethioperm
All patients with a permanent ostomy visiting the stoma center in Addis Abeba
|
EQ5D-5L and Stoma QoL
|
|
EthioTemp
All patients waiting for ostomy reversal at Tikur Anbessa Specialized Hospital
|
EQ5D-5L and Stoma QoL
|
|
SweSto
All patients visiting the stoma clinic at South General Hospital
|
EQ5D-5L and Stoma QoL
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
General quality of life
Time Frame: October 2022 to Jan 2023
|
Overall health through visual analogue scale (VAS) from zero (the worst imaginable health) to 100 (the best imaginable health) from the European Quality of Life 5 Dimensions 5 Level Version (EQ5D-5L).
|
October 2022 to Jan 2023
|
|
Stoma-specific quality of life
Time Frame: October 2022 to Jan 2023
|
The Stoma Quality of life questionnaire consists of 20 questions about stoma-specific aspects of quality of life where each variable is valued equally.
Answers are graded in a four-point scale; 1: always, 2: sometimes, 3: rarely, and 4: not at all, with a maximum score of 80.
The higher score the better QoL.
To get a comparable overall result, the total score (range 20-80) can be converted to a zero to 100 score.
|
October 2022 to Jan 2023
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Stoma complications
Time Frame: October 2022 to Jan 2023
|
Nipple necrosis, prolapse, parastomal hernia, leakage, itching, bleeding, pain
|
October 2022 to Jan 2023
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Åsa Everhov, MD PhD, Karolinska Institutet
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- 008/21/Surg
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stoma Ileostomy
-
NCT07138326RecruitingIleostomy - Stoma | Absorption | Stoma Ileostomy | Pharmakokinetic | Colostomy - Stoma
-
NCT06461559RecruitingIleostomy; Complications | Stoma Ileostomy
-
NCT03982875UnknownIleostomy; Complications | Ileostomy - Stoma
-
NCT04202666UnknownStoma Ileostomy | Stoma Colostomy
-
NCT02043782CompletedStoma Ileostomy | Stoma Colostomy
-
NCT03424447UnknownIleostomy; Complications | Ileostomy - Stoma | Stoma Ileostomy | Ileus Paralytic
-
NCT05373888RecruitingEnterostomy | Stoma Ileostomy | Stoma Colostomy
-
NCT06320002CompletedSurgery | Ileostomy - Stoma | Colostomy Stoma
-
NCT05048329CompletedIleostomy; Complications | Ileostomy - Stoma
-
NCT06897163CompletedIleostomy - Stoma
Clinical Trials on Quality of life assessment
-
NCT01080521CompletedOvarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Serous Cystadenocarcinoma | Stage IV Ovarian Germ Cell Tumor | Ovarian Sarcoma | Malignant Ovarian Epithelial Tumor | Ovarian Carcinosarcoma | Ovarian Brenner Tumor | Ovarian Mucinous Cystadenocarcinoma
-
NCT01506440CompletedUnspecified Adult Solid Tumor, Protocol Specific | Malignant Neoplasm
-
NCT01325753WithdrawnLung Metastases | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Recurrent Malignant Mesothelioma | Advanced Malignant Mesothelioma
-
NCT04670874RecruitingCutaneous Lymphoma
-
NCT04551378RecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | COVID-19 Infection
-
NCT04650178Active, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Neuropathy | COVID-19 Infection
-
NCT00791635Active, not recruitingCervical Carcinoma | Endometrial Carcinoma | Vaginal Carcinoma | Malignant Female Reproductive System Neoplasm | Vulvar Carcinoma
-
NCT04500600Active, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | COVID-19 Infection
-
NCT03057639Terminated
-
NCT04096417Active, not recruitingMetastatic Colorectal Carcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | FGFR1 Gene Amplification